Stem Cell Expansion Hollow-Fiber Bioreactors Market Report 2026

The stem cell expansion hollow-fiber bioreactors market size has grown rapidly in recent years. It will grow from $1.42 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to increasing adoption of hollow-fiber bioreactors, growing demand for high-density stem cell cultures, rising investment in regenerative medicine research, expansion of automated cell expansion technologies, and increasing utilization of single-use bioreactor systems.

The stem cell expansion hollow-fiber bioreactors market size is expected to see rapid growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to rising focus on scalable stem cell production, growing investment in advanced hollow-fiber bioprocessing, increasing demand for clinical-grade stem cell expansion, expansion of biotechnology and pharmaceutical research and development (R&D), and strongly increasing adoption of automated and high-precision platforms. Major trends in the forecast period include technology advancements in micro-hollow-fiber systems, innovations in automated cell expansion platforms, developments in high-density stem cell culture techniques, research and developments in single-use hollow-fiber bioreactors, and advancements in real-time monitoring and process control.

The increasing demand for gene therapies is expected to drive the growth of the stem cell expansion hollow fiber bioreactors market in the coming years. Gene therapy is a medical approach that involves modifying, replacing, or correcting defective genes to treat or prevent disease. The rising demand for gene therapy is driven by advances in genetic sequencing and diagnostic technologies, which allow for accurate identification of disease-causing genes and enable targeted treatment strategies. Stem cell expansion hollow fiber bioreactors support gene therapy by facilitating large-scale, high-quality stem cell expansion under tightly controlled conditions. They enhance therapeutic outcomes by providing a consistent and reliable supply of genetically modified cells for precise and effective gene-based treatments. For example, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the US Food and Drug Administration approved six gene therapy products in 2023, compared with five approvals in 2022. As a result, the growing demand for gene therapies is fueling the growth of the stem cell expansion hollow fiber bioreactors market.

Major companies operating in the stem cell expansion hollow fiber bioreactors market are concentrating on the development of advanced products, such as single-use bioreactors with specialized mixing and nutrient delivery systems, to enhance process control, maintain cell viability, and support scalable manufacturing. Single-use bioreactor technology for advanced therapies refers to a new generation of bioreactors designed to address the limitations of traditional stirred-tank systems used in the production of sensitive cell-based therapies, employing closed and automated platforms to reduce contamination risk and improve performance. For example, in March 2025, ABEC, a US-based biotech manufacturing company, introduced the Advanced Therapy Bioreactor (ATB). This innovative single-use bioreactor platform features a patented design that replicates the human circulatory system by using proprietary hollow fiber membrane networks to enable localized nutrient delivery and efficient waste removal. It incorporates an oscillation-based mixing system and diffusion-based gas transfer to maintain optimal growth conditions for delicate cell types such as primary T-cells and CD34+ stem cells, without the need for bubbles or mechanical agitation. The platform also offers seamless scalability from 0.2 liters to 10 liters by preserving a constant ratio between hollow fiber surface area and bioreactor volume, ensuring consistent performance from early-stage development through commercial manufacturing for partners in the advanced therapy sector.

In December 2024, Getinge AB, a Sweden-based medical technology and bioprocess equipment provider, partnered with 908 Devices Inc. to advance hollow-fiber bioreactor systems for stem cell expansion and bioprocess monitoring. Through this collaboration, Getinge AB and 908 Devices Inc. seek to integrate advanced real-time analytical technologies into Getinge’s bioreactor platforms to enhance process control, cell growth monitoring, and product consistency within stem cell manufacturing workflows. 908 Devices Inc. is a US-based analytical and bioprocess solutions company.

Major companies operating in the stem cell expansion hollow-fiber bioreactors market are Veolia Environnement S.A., Thermo Fisher Scientific Inc., General Electric Company, Mitsubishi Chemical Corporation, Merck KGaA, Kubota Corporation, DuPont de Nemours Inc., Alfa Laval AB, Terumo BCT Inc., Cytiva Sweden AB, MANN+HUMMEL GmbH, Sartorius AG, Eppendorf SE, Repligen Corporation, Pall Corporation, PBS Biotech Inc., Bioengineering AG, Cell Culture Company LLC, FiberCell Systems Inc., FibraCast Inc.

North America was the largest region in the stem cell expansion hollow-fiber bioreactors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell expansion hollow-fiber bioreactors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell expansion hollow-fiber bioreactors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have impacted the stem cell expansion hollow-fiber bioreactor market by increasing costs of imported bioprocessing equipment, membranes, polymers, and precision manufacturing components. these effects are most evident in research institutions, biopharmaceutical manufacturers, and regenerative medicine facilities, particularly across north america, europe, and asia-pacific regions with globally integrated supply chains. higher tariffs have influenced capital expenditure decisions and procurement timelines. however, tariffs have also encouraged local manufacturing, regional supplier development, and innovation in cost-efficient bioreactor systems, supporting long-term market resilience.

A stem cell expansion hollow-fiber bioreactor is a specialized bioprocessing system that utilizes hollow fibers to create a controlled environment for stem cell proliferation. It enables efficient exchange of nutrients and gases while maintaining optimal conditions for cell growth. These systems are widely used in regenerative medicine and research to generate high-density stem cell cultures with strong viability and preserved functionality.

The primary product types of stem cell expansion hollow-fiber bioreactors are single-use hollow-fiber bioreactors and reusable hollow-fiber bioreactors. Single-use hollow-fiber bioreactors are disposable bioprocessing systems designed to support sterile, scalable, and controlled expansion of stem cells for clinical and research applications. These bioreactors utilize technologies such as hollow-fiber systems, microfluidic bioprocessing, single-use bioreactor platforms, automated expansion platforms, and high-precision monitoring technology, distributed through hospital pharmacies, online pharmacies, and retail pharmacies, used in applications including clinical research, cell therapy, tissue engineering, drug development, and others, among end users including biotechnology companies, pharmaceutical companies, academic and research institutes, and others.

The stem cell expansion hollow-fiber bioreactors market consists of revenues earned by entities by providing services such as bioreactor system installation, process optimization support, cell culture protocol development, validation and qualification services, and technical maintenance and training. The market value includes the value of related goods sold by the service provider or included within the service offering. The stem cell expansion hollow-fiber bioreactors market also includes sales of hollow-fiber bioreactor systems, disposable cartridges, perfusion and control units, integrated monitoring sensors, and associated consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.